Dr. Wangzhi Li covers small-to-mid cap biotech companies in oncology and other therapeutic areas. Prior to his current role, Dr. Li worked with Matt Kaplan in covering small-to-mid cap biopharma companies in oncology, endocrinology, nephrology, gastroenterology, ophthalmology, pain and drug delivery etc. Before joining in Ladenburg, Dr. Li worked in healthcare venture capital at Easton Capital and New York City Investment Fund. Dr. Li did his PhD research in cancer biology and epigenetics at Cold Spring Harbor Laboratory, New York and published multiple papers in Nature Communications, Epigenomics, Nature Cell Biology and Cell Stem Cell etc. Dr. Li received his bachelor's degree in biological science from Xiamen University, China.